This perspective on discontinued cardiovascular drugs is the first in a series of papers on drugs dropped from clinical development in 2006. The compounds described in this perspective have been removed from development in various stages and for different reasons. This paper hereby provides a translational medicine perspective on these compounds based on information available through the Pharmaprojects pipeline database. In particular, potential gaps in the pipeline, due to a lack of biomarkers and translational medicine perspectives are emphasized.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1517/13543784.16.9.1315 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!